Targeting Toll-like receptors: Emerging therapeutics for multiple sclerosis management

M. Gambuzza, N. Licata, E. Palella, D. Celi, V. Foti Cuzzola, D. Italiano, S. Marino, P. Bramanti

Research output: Contribution to journalArticlepeer-review


Toll-like receptors (TLR) are important innate immune proteins for the identification and clearance of invading pathogen. TLR signal through adaptor proteins, most commonly myeloid differentiation primary response gene 88 (MyD88). Inappropriate response of specific TLR has been implicated in certain autoimmune diseases, such as multiple sclerosis (MS). Activation of TLR2, TLR4, TLR7 and TLR9 plays a role in experimental allergic encephalomyelitis (EAE), a murine model of MS, while TLR3 activation protects from disease. Therefore, TLR-modulation could be an important adjuvant to current treatments. Here, we focus on TLR involved in EAE and MS pathogenesis highlighting specific components targeting TLR that might offer further therapeutic possibilities.

Original languageEnglish
Pages (from-to)1-12
Number of pages12
JournalJournal of Neuroimmunology
Issue number1-2
Publication statusPublished - Oct 28 2011


  • Innovative therapeutics
  • Multiple sclerosis
  • Receptor-targeting
  • Toll-like receptors

ASJC Scopus subject areas

  • Immunology
  • Clinical Neurology
  • Immunology and Allergy
  • Neurology


Dive into the research topics of 'Targeting Toll-like receptors: Emerging therapeutics for multiple sclerosis management'. Together they form a unique fingerprint.

Cite this